Profile
Arthur M.
Krieg is the founder of Coley Pharmaceutical Group, Inc. (founded in 1997), Translate Bio, Inc. (founded in 2011), and Checkmate Pharmaceuticals, Inc. (founded in 2015).
At Coley Pharmaceutical Group, Inc., he held the title of Chief Scientific Officer & Senior Vice President from 1997 to 2011.
At Translate Bio, Inc., he held the title of Chief Executive Officer from 2011 to 2013.
At Checkmate Pharmaceuticals, Inc., he held the titles of CEO, Director & Chief Scientific Officer from 2015 to 2018.
Dr. Krieg's former jobs included Chief Executive Officer at Translate Bio, Inc. from 2011 to 2014, Director at Cytos Biotechnology AG from 2012 to 2014, Chief Scientific Officer & Senior Vice President at Sarepta Therapeutics, Inc. in 2014, Professor at the University of Iowa, and Chief Scientific Officer at Oligonucleotide Therapeutics Society, Inc. from 2008 to 2011.
Dr. Krieg's education includes a doctorate from the University of Washington and an undergraduate degree from Haverford College.
Former positions of Arthur M. Krieg
| Companies | Position | End |
|---|---|---|
| CHECKMATE PHARMACEUTICALS, INC. | Chief Executive Officer | 2018-12-11 |
| SAREPTA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2014-07-21 |
Cytos Biotechnology AG
 Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | Director/Board Member | 2014-05-30 |
| TRANSLATE BIO, INC. | Chief Executive Officer | 2013-12-31 |
| TRANSLATE BIO, INC. | Chief Executive Officer | 2012-12-31 |
Training of Arthur M. Krieg
| University of Washington | Doctorate Degree |
| Haverford College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| Private companies | 6 |
|---|---|
Coley Pharmaceutical Group, Inc.
 Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA | Health Technology |
Translate Bio, Inc.
 Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | Commercial Services |
Oligonucleotide Therapeutics Society, Inc.
 Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The private company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Commercial Services |
| National Institute of Arthritis | Government |
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Arthur M. Krieg